

TECH CENTER 1600/2900

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.
038602-1325

SERIAL NO.
10/076,621

INFORMATION DISCLOSURE CITATION

APPLICANT

Peng Cho TANG et al.

FILING DATE

02/19/2002

GROUP ART UNIT

1645 1626

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
JS	A1	Re 36,256	07/20/1999	Spada et al.	11	11	
JS	A2	2,872,372	02/03/1959	Hull	11	11	
JS	A3	2,968,557	01/17/1961	Burgardt et al.	11	11	
JS	A4	4,002,749	01/11/1977	Rovnyak	11	11	
JS	A5	4,053,613	10/11/1977	Rovnyak et al.	11	11	
JS	A6	4,376,110	03/08/1983	David et al.	11	11	
JS	A7	4,642,309	02/10/1987	Michel et al.	11	11	
JS	A8	4,826,847	05/02/1989	Michel et al.	11	11	
JS	A9	4,853,403	08/01/1989	Shiraishi et al.	11	11	
JS	A10	4,868,304	09/19/1989	Larock et al.	11	11	
JS	A11	4,966,849	10/30/1990	Vallee et al.	11	11	
JS	A12	4,971,996	11/20/1990	Shiraishi et al.	11	11	
JS	A13	5,051,417	09/24/1991	Nadler et al.	11	11	
JS	A14	5,057,538	10/15/1991	Shiraishi et al.	11	11	
JS	A15	5,089,516	02/18/1992	Shiraishi et al.	11	11	
JS	A16	5,124,347	06/23/1992	Connor et al.	11	11	
JS	A17	5,202,341	04/13/1993	Shiraishi et al.	11	11	
JS	A18	5,206,261	04/1993	Kawaguchi et al.	11	11	
JS	A19	5,217,999	06/08/1993	Levitzi et al.	11	11	
JS	A20	5,302,606	04/12/1994	Spada et al.	11	11	
JS	A21	5,322,950	06/1994	Sircar et al.	11	11	
JS	A22	5,330,992	07/19/1994	Eissenstat et al.	11	11	
JS	A23	5,374,652	12/20/1994	Buzzetti et al.	11	11	
JS	A24	5,382,593	01/1995	Le Baut	11	11	
JS	A25	5,397,787	03/14/1995	Buzzetti et al.	11	11	
JS	A26	5,409,949	04/1995	Buzzetti et al.	11	11	
JS	A27	5,463,052	10/31/1995	Haga et al.	11	11	
JS	A28	5,786,488	07/28/1998	Tang et al.	11	11	
JS	A29	5,792,783	08/11/1998	Tang	11	11	
JS	A30	5,840,745	11/24/1998	Buzzetti et al.	11	11	
JS	A31	5,849,710	12/15/1998	Battistini et al.	11	11	
JS	A32	5,880,141	03/09/1999	Tang et al.	11	11	

RECEIVED
AUG 09 2002
TECH CENTER 1600/2900

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 038602-1325 SERIAL NO. 10/076,621

APPLICANT Peng Cho TANG et al.

FILING DATE 02/19/2002 GROUP ART UNIT 1626 1645


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

585	A33	5,883,113	03/16/1999	Tang et al.	/	RECEIVED
585	A34	5,883,116	03/16/1999	Tang et al.	/	
585	A35	5,886,020	03/23/1999	Tang et al.	/	AUG 09 2002
585	A36	6,130,238	10/2000	Tang et al.	/	
585	A37	6,147,106	11/2000	Tang et al.	/	TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	A38	286870	12/04/1964	AU	/	/		
	A39	2,012,634	09/20/1991	CA	/	/		
	A40	878539	06/05/1953	DE	/	/		
	A41	2,159,360	06/14/1973	DE	/	/		
	A42	2,159,361	06/14/1973	DE	/	/		
	A43	2,159,362	06/14/1973	DE	/	/		
	A44	2,159,363	06/14/1973	DE	/	/		
	A45	2,321,656	11/15/1973	DE	/	/		
	A46	3,310,891	09/27/1984	DE	/	/		
	A47	3,426,419	01/23/1986	DE	/	/		
	A48	0 252 713	01/13/1988	EP	/	/		
	A49	0 351 213	01/17/1990	EP	/	/		
	A50	0 566 226	01/15/1993	EP	/	/		
	A51	0 525 472	02/03/1993	EP	/	/		
	A52	0 580 502	01/26/1994	EP	/	/		
	A53	0 632 102	06/15/1994	EP	/	/		
	A54	0 626 377	11/30/1994	EP	/	/		
585	A55	0 632 102	04/01/1995	EP	/	/		
	A56	0 602 473	07/12/1995	EP	/	/		
	A57	0 788 890	08/13/1997	EP	/	/		
585	A58	1,398,224	03/29/1965	FR	/	/		
	A59	2,689,397	10/08/1993	FR	/	/		
	A60	Unknown	10/12/1992	HU	/	/		
	A61	62-29570	02/07/1987	JP	/	/		
	A62	62-39564	02/20/1987	JP	/	/		
	A63	63-141955	06/14/1988	JP	/	/		
	A64	558894	03/09/1993	JP	/	/		
	A65	92-86777	11/04/1997	JP	/	/		



Form PTO-1449
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

038602-1325

SERIAL NO.

10/076,621

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Peng Cho TANG et al.

FILING DATE

02/19/2002

GROUP ART UNIT

1626 1645

	A66	809691	03/04/1959	UK					
	A67	835473	05/18/1960	UK					
	A68	1,384,599	02/19/1975	UK					
	A69	88/07035	09/22/1988	WO					
	A70	91/13055	09/05/1991	WO					
	A71	91/15495	10/17/1991	WO					
	A72	92/21660	04/10/1992	WO					
	A73	92/07830	05/14/1992	WO					
	A74	92/20642	11/26/1992	WO					
	A75	92/21660	12/10/1992	WO					
885	A76	93/01182	01/21/1993	WO					
	A77	93/23040	11/25/1993	WO					
	A78	94/03427	02/17/1994	WO					
	A79	94/10202	05/11/1994	WO					
	A80	94/14808	07/07/1994	WO					
	A81	95/01349	01/12/1995	WO					
	A82	95/14667	06/01/1995	WO					
885	A83	95/17181	06/29/1995	WO					
	A84	95/24190	09/14/1995	WO					
	A85	96/00226	01/04/1996	WO					
	A86	96/16964	06/06/1996	WO					
885	A87	96/22976	08/01/1996	WO					
885	A88	96/32380	10/17/1996	WO					
885	A89	96/40116	12/19/1996	WO					
885	A90	97/25986	07/24/1997	WO					
	A91	97/36867	10/09/1997	WO					
	A92	98/07695	02/26/1998	WO					
	A93	98/07835	02/26/1998	WO					
	A94	98/45708	10/15/1998	WO					
	A95	98/50356	11/12/1998	WO					
	A96	98/56376	12/17/1998	WO					
885	A97	99/10325	03/04/1999	WO					

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Peng Cho TANG et al.	
		FILING DATE 02/19/2002	GROUP ART UNIT 1626 1645
A98	Abramovitch and Hey, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," <u>J. Chem. Soc. pp.</u> 1697-1703 (1954)		
A99	Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <u>Chemistry and Industry</u> 44:1871 (1967)		
A100	Abramovitch, Beilstein Reg. No. 236050, <u>J. Chem. Soc.</u> , pages 1697, 1700 (1954)		
A101	Akbasak and Suner-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)		
A102	Andreani et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48 (II): 727-729(1998)		
A103	Andreani et al., "Potential antitumor agents. 25[1]. Synthesis and cytotoxic activity of 3-(2-chloro-3-indolylmethylene) 1,3-Dyhydroindol-2-ones," <u>AntiCancer Research</u> 16:3585-3588 (1996)		
A104	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)		
A105	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 78106 (1990)		
A106	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993)		
A107	Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992)		
A108	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2, 1-b]thiazolymethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997)		
A109	Andreani et al., "Synthesis of lacatams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)		
A110	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)		
A111	Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994)		
A112	Autrey and Tahk, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967)		
A113	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)		
A114	Bamfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> pp. 1028-1030 (1966)		
A115	Baserga, "Oncogenes and the strategy of growth factors," <u>Cell</u> 79:927-930 (1994)		
A116	Baserga, "The insulin-like growth factor I receptor: a key to tumor growth?" <u>Cancer Res.</u> 55:249-252 (1995)		
A117	Beilstein Reg. No. 235647 (1997)		
A118	Beilstein Reg. No. 233511 (1997)		

Form PT-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1325		SERIAL NO. 10/076,62	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Peng Cho TANG et al.			
				FILING DATE 02/19/2002		GROUP ART UNIT 1626 1645	
	A119	Beilstein Reg. No.: 252929 (1923)					
	A120	Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> pp. 1660-1663 (1973)					
	A121	Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>Chemical Abstracts</u> , Vol. 80, abstract no. 26692 (1974)					
	A122	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)					
	A123	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)					
	A124	Bonner et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1986)					
	A125	Borsche et al., "Über nielkernige kondensierte systeme mit heterocyclischen ringen," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)					
	A126	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48(5):615-636 (1993)					
	A127	Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993)					
	A128	Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)					
	A129	Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997)					
	A130	Chao, "Growth Factor Signaling: Where is the Specificity?" <u>Cell</u> 68:995-997 (1992)					
	A131	Chatten et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones," <u>J. Chem. Soc. Perkin II</u> pp. 469-473 (1973)					
	A132	Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40(3):149-156 (1997)					
	A133	Claesso-Welsh, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994)					
	A134	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin II</u> pp. 615-619 (1984)					
	A135	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>Chemical Abstracts</u> , Vol. 101, abstract no. 37875 (1984)					
	A136	Coda et al., "3-(4-methylbenzylidene)-1,3-dihydroindol-2-one," <u>J. Chem. Soc. Perkin II</u> , Database Crossfire, Beilstein Ref. No. 6-21, 4: 615-620 (1984)					
	A137	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994)					

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Peng Cho TANG et al.	
				FILING DATE 02/19/2002	GROUP ART UNIT 1626 1645
A138	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974)				
A139	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>Chemical Abstracts</u> Vol. 82, abstract no. 72891 (1975)				
A140	Damiani et al., "Inhibition of Cooper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48(6):1155-1161 (1994)				
A141	Dati et al., "Inhibition of <i>c-erbB-2</i> oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)				
A142	Davis et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16(9):1043-1045 (1973)				
A143	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988)				
A144	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)				
A145	Dickson et al., "Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)				
A146	Elliot, "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Database Crossfire, Beilstein Ref. No. 5-24, March 19, 1991, XP 002049951				
A147	Elliott and Rivers, "Reduction of some oxindolide derivatives to 3-substituted oxindoles by sodium borohydride," <u>J. Organic Chem.</u> 29:2438-2440 (1964)				
A148	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992)				
A149	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human or Epidermal Growth Factor Receptor or HER2/ <i>neu</i> Gene Product" <u>Cancer Research</u> 50:1550-1558 (1990)				
A150	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989)				
A151	Fingl and Woodbury, Chapter 1, pp. 1-46 in <u>The Pharmacological Basis of Therapeutic</u> (5 th edition), eds. Goodman et al., MacMillan Publishing Co., Inc., New York (1975)				
A152	Floege et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro in vivo</i> ," <u>Kidney International</u> 43S:47-54 (1993)				
A153	Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993)				
A154	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992)				
A155	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)				

Form PTO-449
(MODIFIED) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

038602-1325

SERIAL NO.

10/076,621

APPLICANT

Peng Cho TANG et al.

FILING DATE

02/19/2002

GROUP ART UNIT

1626 +645

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

A156	Folkman, "Ch. 24. Angiogenesis, <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
A157	Folkman, "Tumor Angiogenesis: Therapeutic Implications" <u>New England J. Medicine</u> 285:1182-1186 (1971)
A158	Gazit et al., "Tyrophostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2-neu tyrosine-kinases," <u>J. Med. Chem.</u> 34(6):1896-1907 (1991)
A159	Gennaro (editor), <u>Remington's Pharmaceutical Sciences</u> (1990)(TABLE OF CONTENTS ONLY)
A160	Goldring and Goldring, "Cytokines and cell growth control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)
A161	Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30(1-6):311-314 (1988)
A162	Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268(13):9165-9168 (1993)
A163	Hewgill and Stewart, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J. Chem. Soc. Perkin Trans. I</u> pp. 1305-1311 (1988)
A164	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)
A165	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987)
A166	Houben-Weyl, "Substance Index," <u>Cyclic Compounds & Bicyclic Compounds 1</u> E231:834-1018 (1999)
A167	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992)
A168	Howard et al., Provisional Patent Application No. 60/015,134 filed March 29, 1996 for "Lactam Derivatives"
A169	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992)
A170	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1 acetic acids" <u>Chemical Abstracts</u> , Vol. 118, abstract no. 254813 (1993)
A171	Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12(3):981-990 (1992)
A172	Ijaz et al., "The Conversion of α,β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>J. Chem. Res. (S)</u> pp. 116 (1990)
A173	Ijaz et al., "The Conversion of α,β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 93739 (1990)
A174	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
A175	Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993)

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,6
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Peng Cho TANG et al.	
				FILING DATE 02/19/2002	GROUP ART UNIT 1626-1645
A176	Kashishian et al., "Phosphorylation Sites in the PDGF receptor with Different Specificities for Binding GAP and P13 Kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11(4):1373-1382 (1992)				
A177	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993).				
A178	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)				
A179	Kazlauskas et al., "The 64-kDa Protein That Associates with the Platelet-Derived Growth Factor Receptor β Subunit via Tyr-1009 Is The SH2-Containing Phosphotyrosine Phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)				
A180	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)				
A181	Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> , 54:904-907 (1977)				
A182	Kim et al., "Inhibition of Vascular endothelial growth factor-induced angiogenesis suppresses tumor growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)				
A183	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:52-62 (1992)				
A184	Klagsburn and Soker, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993)				
A185	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97(9):1033-1039 (1977)				
A186	Koch et al., "SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signalling Proteins," <u>Science</u> 252:668-674 (1991)				
A187	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975)				
A188	Komada et al., "The cell dissemination and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)				
A189	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992)				
A190	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity ¹ ," <u>J. Immunol. Methods</u> 64:313-320 (1983)				
A191	Kovac and Stetinova, "Furan derivatives LXXX. Synthesis and properties of substituted furfurylidenoxindoles," <u>Chem. vesu</u> 30:484-492 (1976)				
A192	Krueger and Saito, "A human transmembrane protein-tyrosine-phosphatase, PTP, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> 89:7417-7421 (1992)				
A193	Kumbae et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)				

Form PTO-1449

(MODIFIED)

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

038602-1325

SERIAL NO.

10/076,621

APPLICANT

Peng Cho TANG et al.

FILING DATE

02/19/2002

GROUP ART UNIT

1626 1645

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

- | | |
|------|---|
| A194 | Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:52991-52994 (1987) |
| A195 | Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992) |
| A196 | Levitcki and Gazit, "Tyrosine kinase inhibition: An approach to drug development," <u>Science</u> 267:1782-1788 (1995) |
| A197 | Maas et al., "Viral resistance to the thiazolo-iso-indolines, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37(12):2612-2617 (1993) |
| A198 | Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517 (1990) |
| A199 | Mariani et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (1994) |
| A200 | Martin-León et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring," <u>Liebigs Ann. Chem.</u> pp. 101-104 (1990) |
| A201 | Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) |
| A202 | Mirand et al., "A Synthetic Entry in the <i>Aristofolia</i> Alkaloids," <u>J. Org. Chem.</u> 47:4169-4170 (1982) |
| A203 | Mohammad et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," <u>Science</u> 276:955-960 (1997) |
| A204 | Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29(II):1561-1564 (1979) |
| A205 | Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (Dan-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) |
| A206 | Morrison et al., "Signal transduction from membrane to cytoplasm: Growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988) |
| A207 | Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) |
| A208 | Nöber and Rocker, "Ueber die einwirkung von benzaldehyden auf die freie o-aminophenyl-essigsäure," <u>Chem. Ber.</u> 56:1710-1717 (1923) (with translation) |
| A209 | Nishimura et al., "Two Signaling Molecules Share a phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993) |
| A210 | Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 765, abstract no. 21121 (1972) |

RECEIVED

AUG 21 2002

TECH CENTER 1600 2900

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.

038602-1325

SERIAL NO.

10/076,621

APPLICANT

Peng Cho TANG et al.

FILING DATE

02/19/2002

GROUP ART UNIT

1626-1545

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

A211	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)
A212	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)
A213	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975)
A214	Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)
A215	Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)
A216	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr. RSR</u> 7:64-66 (1980)
A217	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <i>in vivo</i> ," <u>Nature</u> 359:845-848 (1992)
A218	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)
A219	Quinn et al., "Fetal Liver Kinase 1 is a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)
A220	Rozakis-Adcock et al., "Association of the Shc and Grb2-Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)
A221	Ruveda and Gonzalez, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)
A222	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)
A223	Saito and Streuli, "Molecular Characterization of Protein Tyrosine Phosphatases," <u>Cell Growth & Differentiation</u> 2:59-65 (1991)
A224	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," <u>Cancer Res.</u> 53:2475-2478 (1993)
A225	Schindler et al., "Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)
A226	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992)
A227	Schmerle et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," <u>Liebigs Ann. Chem.</u> 715:90-97 (1968)
A228	Schuchter et al., "Successful Treatment of Murine Melanoma With Bryostatins 1," <u>Cancer Research</u> 51:682-687 (1991)
A229	Seibert et al., "Clonal Variation of MCF-7 Breast Cancer Cells <i>in Vitro</i> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983)
A230	Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67(1):51-56 (1981)

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			APPLICANT Peng Cho TANG et al.	
			FILING DATE 02/19/2002	GROUP ART UNIT 1626 1645
A231	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <u>Oncogene</u> 5:519-524 (1990)			
A232	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives in Vitro," <u>Cancer Research</u> 49:2374-2378 (1989)			
A233	Shiraishi, "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4- Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987)			
A234	Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)			
A235	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989)			
A236	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)			
A237	Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)			
A238	Slamon et al., "Studies of the HER/2- <i>neu</i> Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)			
A239	Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13(3):515-525 (1996)			
A240	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993)			
A241	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994)			
A242	Spada and Myers, "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5(8):805-817 (1995)			
A243	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1976)			
A244	Stolle, Beilstein Reg. No. 273650, <u>J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)			
A245	Sumpter and Miller, "Chapter IV - Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , Interscience Publishers, Inc., New York, pp. 134-153 (1954)			
A246	Sun et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998)			
A247	Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech</u> 14:600-605 (1996)			
A248	Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993)			
A249	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)			

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			APPLICANT Peng Cho TANG et al.	
			FILING DATE 02/19/2002	GROUP ART UNIT 1626 1645
	A250	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> pp. 150-154 (1976)		
	A251	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A (1993), at abstract no. 2076		
888	A252	Terrett et al., "Combinatorial synthesis- the design of compound libraries and their application to drug discovery," <u>Tetrahedron</u> 51(30):8135-8173 (1995)		
	A253	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> pp. 1835-1837 (1993)		
	A254	Torp et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," <u>AMPIS</u> 100:713-719 (1992)		
	A255	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997)		
	A256	Treibs et al., "Uber isoindigoide Farbstoffe der Pyrrol-Reihe," <u>Liebigs Ann. Chem.</u> 702:112-130 (1967)		
	A257	Trost et al. (ed.), "Comprehensive Organic Synthesis," Selectivity, Strategy & Efficiency in Modern Organic Chemistry 4:478 (1991)		
	A258	Tsai et al., "The Effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31(9):943-947 (1992)		
	A259	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)		
	A260	Twamley-Stein et al., "The Src Family Tyrosine Kinases are Required for Platelet-Derived Growth Factor-Mediated Signal Transduction in NIH-3T3 Cells," <u>Proc. Natl. Acad. Sci.</u> 90:7696-7700 (1993)		
	A261	Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990)		
	A262	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990)		
	A263	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carboxymethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989)		
	A264	Voller et al., "Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington D.C., pp. 359-371 (1980)		
	A265	von Dobeneck et al., " α,β -Diindolylmethane und-methene. Der Urorosein-Chromophor," <u>Zur Chemie des Indols VI</u> :1347-1357 (1969)		
	A266	Wahl et al., "Chimie Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (July 1909)		
	A267	Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim.</u> , Database Crossfire, Beilstein Ref. No. 2-21-00-00290, p. 350 (1926)		
	A268	Wahl, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)		
	A269	Wahl, Beilstein Reg. No. 231732, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909)		

RECEIVED

TECH CENTER 1600 2900

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE
PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.

038602-1325

SERIAL NO.

10/076,621

INFORMATION DISCLOSURE CITATION

APPLICANT

Peng Cho TANG et al.

FILING DATE

02/19/2002

GROUP ART UNIT

1626 1645

(Use several sheets if necessary)

- | | |
|------|--|
| A270 | Walker, "The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965) |
| A271 | Walker, "Synthesis of a α -(p-Aminophenyl)- and α -(p-Chlorophenyl)- β -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8(5):583-588 (1965) |
| A272 | Walker, "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)- and 3-(β -Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965) |
| A273 | Warri et al., "Estrogen Suppression of <i>erbB2</i> Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells <i>In Vitro</i> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991) |
| A274 | Weidner et al., "Tumor Angiogenesis and Metastasis -- Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) |
| A275 | Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4, 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27(II) 2251-2263 (1977) |
| A276 | Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956) |
| A277 | Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992) |
| A278 | Wright, Beilstein Reg. No. 244658, <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956) |
| A279 | Wright, Beilstein Reg. No. 235900, <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956) |
| A280 | Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, A Reversible Redox Substrate at the Carbon Paste Electrode in Acidic Aqueous-Ethanol Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982) |
| A281 | Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999) |
| A282 | Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:288-294 (1996) |
| A283 | Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Institute of Chemistry, Academy of Science of the Moldavian SSR, Kishinev pp. 34-37 translated from Khimiya Geterotsiklicheskih Soedinenii</u> 1:40-44 (1973) |
| A284 | Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Chemical Abstracts</u> , Vol. 78, abstract no. 111201 (1973) |

EXAMINER

DATE CONSIDERED

5/2/03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

RECEIVED